Drug intelligence / Profile preview

KN713

Development stage: Phase 2
Lead developer: New Cancer Cure-Bio Co., Ltd
Modality: Small Molecules
Administration: Oral

Overview

KN713 is a small molecule drug in development as an inhibitor of acetyl-CoA acyltransferase 1 (ACAA1), a key enzyme involved in peroxisomal beta-oxidation and fatty acid metabolism. It is being developed by New Cancer Cure-Bio for the treatment of advanced solid tumors, with the aim to disrupt cancer cell energy production by targeting metabolic pathways rather than specific oncogenic mutations. By inhibiting fatty acid oxidation, KN713 may deplete ATP levels in tumor cells, potentially overcoming resistance mechanisms associated with traditional targeted therapies[1][2][4][6].

Targets

ACAT1 (Acyl-coenzyme A:cholesterol O-acyltransferase 1)

Beyond the preview

Go deeper on KN713.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KN713.

Explore the full profile